Search in:

Advanced search

Journal of Dermatological Treatment Volume 28, 2017 - Issue 6

Submit an article Journal homepage

Open access

1,577

Views

CrossRef citations to date

Altmetric

Treatment

Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States

Qiufei MaDepartment of Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA; View further author information

Yaozhu Juliette ChenHealth Economics & Outcomes Research, IMS Health, Fairfax, VA, USA; View further author information

Dionne M. HinesHealth Economics & Outcomes Research, IMS Health, Fairfax, VA, USA; View further author information

Julie MunakataReal World Evidence Solutions, IMS Health, San Francisco, CA, USA; View further author information

Nicolas BattyDepartment of Medical Affairs, Amgen Inc, Thousand Oaks, CA, USAView further author information

Beth Louise BarberDepartment of Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA; View further author information

Zhongyun ZhaoDepartment of Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA; Correspondence[email protected]
View further author information

show all

Pages 549-553 | Received 21 Sep 2016, Accepted 21 Dec 2016, Published online: 19 Jan 2017

Cite this article
https://doi.org/10.1080/09546634.2016.1277176
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Meier F, Nesbit M, Hsu MY, et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol. 2000;156:193–200.
PubMed Web of Science ®Google Scholar
Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:647684. doi:10.1155/2012/647684.
PubMedGoogle Scholar
American Cancer Society [Internet]. Cancer Facts & Figures. US: American Cancer Society; 2015 [cited 2016 Aug 16]. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
Google Scholar
Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270–83.
PubMed Web of Science ®Google Scholar
International Agency for Research on Cancer [Internet]. Globocan. France: IARC; 2015 [cited 2016 Aug 16]. Available from: http://globocan.iarc.fr/Default.aspx.
Google Scholar
Barbato MT, Bakos L, Bakos RM, et al. Predictors of quality of life in patients with skin melanoma at the dermatology department of the Porto Alegre Teaching Hospital. An Bras Dermatol. 2011;86:249–56.
PubMed Web of Science ®Google Scholar
Ekwueme DU, Guy GP Jr, Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol. 2011;65:S133–S43.
PubMed Web of Science ®Google Scholar
Thiam A, Zhao Z, Quinn C, Barber B. Years of life lost due to metastatic melanoma in 12 countries. J Med Econ. 2016;19:1–6.
PubMed Web of Science ®Google Scholar
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.
PubMed Web of Science ®Google Scholar
National Comprehensive Cancer Network [Internet]. NCCN Clinical Guidelines in Oncology. Melanoma. USA: NCCN; 2016 [cited 2016 Aug 16]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Google Scholar
Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview [review]. Oncology (Williston Park, N.Y.). 2009;23:488–96.
PubMed Web of Science ®Google Scholar
Lui P, Cashin R, Machado M, et al. Treatments for metastatic melanoma: synthesis of evidence from randomized trials [review]. Cancer Treat Rev. 2007;33:665–80.
PubMed Web of Science ®Google Scholar
Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000;19:21–34.
PubMed Web of Science ®Google Scholar
Bristol-Myers Squibb [Internet]. Yervoy prescribing information. USA: Bristol-Myer Squibb; 2011 [cited 2016 Aug 16]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf.
Google Scholar
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
PubMed Web of Science ®Google Scholar
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
PubMed Web of Science ®Google Scholar
Genentech [Internet]. Zelboraf Prescribing Information. USA: Genentech; 2015 [cited 2016 Aug 16]. Available from: http://www.gene.com/download/pdf/zelboraf_prescribing.pdf.
Google Scholar
Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.
PubMed Web of Science ®Google Scholar
GlaxoSmithKline [Internet]. Tafinlar Prescribing Information. USA: Novartis; 2015 [cited 2016 Aug 16]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/tafinlar.pdf.
Google Scholar
IMS Health [Internet]. PharMetrics Plus Data Dictionary. USA: IMS Health; 2013. [cited 2016 Aug 16]. Available from: http://tri.uams.edu/files/2015/08/Pharmetrics-Plus-Data-Dictionary-Jan-2013.pdf.
Google Scholar
Toy EL, Vekeman F, Lewis MC, et al. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin. 2015;31:1561–72.
PubMed Web of Science ®Google Scholar
Zhao Z, Wang S, Barber BL. Treatment patterns in patients with metastatic melanoma: a retrospective analysis. J Skin Cancer. 2014;2014:371326. doi:10.1155/2014/371326.
PubMedGoogle Scholar
Hodi FS, O'Day SJ, McDermott DF, et al. Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. J Clin Oncol. 2010;28:15_suppl 8509.
PubMed Web of Science ®Google Scholar
Chiarion-Sileni V, Pigozzo J, Ascierto PA, et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer. 2014;110:1721–26.
PubMed Web of Science ®Google Scholar
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date